BioNTech SE To Discuss Hold Digital Press Conference to Provide an Update on Omicron Variant Call Transcript
Welcome to our digital press conference to provide an update on the Omicron variant. We will start with a presentation by our CEO and Co-Founder, Ugur Sahin, followed by a Q&A session. Ugur, let me hand over to you.
Thank you, Natasha. Hi, everyone. We are here today to present our first preliminary data from a laboratory test evaluating the authorization of the new Omicron spike variant in laboratory assays.
So let me start just with the short disclosures and with some background information. The Omicron -- new Omicron variant, also known as B11529, has multiple mutation at sites which are known to be relevant for binding of the neutralizing antibodies in the spike protein. In total, total, there are 34 to 35 mutations. These mutations are at sites of the receptor binding domain, which directly binds to the ACE2 receptor on target cells as well as in the [internal] domain, which is known to harbor also neutralizing antibody sites.
Many of these mutations, which
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
